Frontiers in Cardiovascular Medicine
Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study
Cohort study of 186 peopleEvolocumab
Papers by Wenlong Jiang
1 result